|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
The Auto Beat
Byte of the Apple
Europe Insight
Eye on Asia
Getting In
Investing Insights
The New Entrepreneur
NEXT: Innovation Tools & Trends
On Media
Technology at Work
The Tech Beat
Traveler's Check
TECHNOLOGY
Product Reviews
Tech Stats
Hands On
AUTOS
Home Page
Auto Reviews
Car Care & Safety
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip FINANCE Investing: Europe Annual Reports Bloomberg BW50 SCOREBOARDS Hot Growth Companies: 2008 Mutual Funds Info Tech 100 B-SCHOOLS Undergrad Programs Rankings & Profiles |  |
FEBRUARY 27, 2006
Pozen's Trexima: Going To Market With Glaxo  Attention, migraine sufferers: Help is on the way from Pozen (POZN
) in the form of Trexima, a new drug for severe headaches that analysts claim is more effective and faster-acting than GlaxoSmithKline's (GSK
) $1 billion-a-year blockbuster Imitrex. It's expected to get U.S. approval in the second quarter. Imitrex' patent expires in 2009, and Pozen has teamed up with Glaxo to market Trexima in the U.S. It will focus on Trexima once it gets O.K.'d, says Pozen CEO John Plachetka. Joshua Schimmer of investment firm S.G. Cowen expects the stock to outscore the market once the new drug is launched. It has already been on a tear, leaping from 8 in August to 17 on Feb. 15. Schimmer figures Pozen will earn 50 cents a share in 2009 and $1.55 in 2010. Nadav Hazan of SunTrust Robinson Humphrey says Pozen should get $20 million from Glaxo once Trexima is approved, on top of the $60 million it has already received. Through 2009, Hazan figures Pozen will get a 6% royalty on U.S. sales of up to $600 million, and 17% above that. In addition, Pozen has an arthritis drug in clinical trials, which the company claims is a lot safer than its rival painkillers.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2006, Bloomberg L.P.Terms of Use | Privacy Notice |
Printer-Friendly Version